A correlation was found between chemoresistance of HT-29CD133+ and HT-29CD133— sublines obtained after cell sorting and high expression of CD133. On the other hand, knockout of the PROM1 gene and, as a consequence, the absence of CD133 expression did not increase the sensitivity of tumor cells to chemotherapy, which indicates the absence of a direct effect of CD133 on the formation of chemoresistance in colorectal cancer cells. Variants of the HT-29 line with complete or partial knockout of the PROM1 gene were equally sensitive to protein kinase inhibitors sorafenib and sunitinib. Notably, the highest resistance to mTOR inhibitors, temsirolimus and everolimus, was shown by cells with complete knockout of the PROM1 gene (KO-HT-29 (P1)). These findings suggest that CD133 is associated with the chemoresistance of colorectal cancer cells, but is not involved in its formation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Corbeil D, Röper K, Fargeas CA, Joester A, Huttner WB. Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic. 2001;2(2):82-91. doi: https://doi.org/10.1034/j.1600-0854.2001.020202.x
Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C, Clarke MF. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl Acad. Sci. USA. 2007;104(24):10158-10163. doi: https://doi.org/10.1073/pnas.0703478104
Gisina AM, Kim YS, Potashnikova DM, Tvorogova AV, Yarygin KN, Lupatov AY. Proliferative activity of colorectal cancer cells with different levels of CD133 expression. Bull. Exp. Biol. Med. 2019;167(4):541-545. doi: https://doi.org/10.1007/s10517-019-04569-y
Gisina AM, Lupatov AY, Karalkin PA, Mainovskaya OA, Petrov LO, Sidorov DV, Frank GA, Yarygin KN. Subpopulation of colorectal adenocarcinoma cells co-expressing CD133 and cancer stem cells markers of other tumors. Bull. Exp. Biol. Med. 2012;152(6):739-742. doi: https://doi.org/10.1007/s10517-012-1620-0
Gisina AM, Lupatov AY, Karalkin PA, Mainovskaya OA, Petrov LO, Sidorov DV, Yarygin VN, Yarygin KN. Detection of minor subpopulations of colorectal adenocarcinoma cells expressing cancer stem cell markers. Bull. Exp. Biol. Med. 2011;151(2):234-238. doi: https://doi.org/10.1007/s10517-011-1297-9
Hongo K, Tanaka J, Tsuno NH, Kawai K, Nishikawa T, Shuno Y, Sasaki K, Kaneko M, Hiyoshi M, Sunami E, Kitayama J, Takahashi K, Nagawa H. CD133(-) cells, derived from a single human colon cancer cell line, are more resistant to 5-fluorouracil (FU) than CD133(+) cells, dependent on the β1-integrin signaling. J. Surg. Res. 2012;175(2):278-288. doi: https://doi.org/10.1016/j.jss.2011.03.076
Kholodenko IV, Kalinovsky DV, Svirshchevskaya EV, Doronin II, Konovalova MV, Kibardin AV, Shamanskaya TV, Larin SS, Deyev SM, Kholodenko RV. Multimerization through pegylation improves pharmacokinetic properties of scFv fragments of GD2-specific antibodies. Molecules. 2019;24(21):3835. doi: https://doi.org/10.3390/molecules24213835
Kim YS, Kaidina AM, Chiang JH, Yarygin KN, Lupatov AY. Molecular markers of cancer stem cells verified in vivo. Biomed. Khim. 2016;62(3):228-238. doi: https://doi.org/10.18097/PBMC20166203228
Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer. 2006;5:67. doi: https://doi.org/10.1186/1476-4598-5-67
Mizrak D, Brittan M, Alison M. CD133: molecule of the moment. J. Pathol. 2008;214(1):3-9. doi: https://doi.org/10.1002/path.2283
O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immuno deficient mice. Nature. 2007;445:106-110. doi: https://doi.org/10.1038/nature05372
Ong CW, Kim LG, Kong HH, Low LY, Iacopetta B, Soong R, Salto-Tellez M. CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod. Pathol. 2010;23(3):450-457. doi: https://doi.org/10.1038/modpathol.2009.181
Park YY, An CH, Oh ST, Chang ED, Lee J. Expression of CD133 is associated with poor prognosis in stage II colorectal carcinoma. Medicine (Baltimore). 2019;98(32):e16709. doi: https://doi.org/10.1097/MD.0000000000016709
Ricci-Vitiani L, Lombardi D. G, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111-115. doi: https://doi.org/10.1038/nature05384
Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK, Chadburn A, Murphy AJ, Valenzuela DM, Gale NW, Thurston G, Yancopoulos GD, D’Angelica M, Kemeny N, Lyden D, Rafii S. CD133 expression is not restricted to stem cells, and both CD133+ and CD133— metastatic colon cancer cells initiate tumors. J. Clin. Invest. 2008;118(6):2111-2120. doi: https://doi.org/10.1172/JCI34401
Simbulan-Rosenthal CM, Gaur A, Zhou H, AbdusSamad M, Qin Q, Dougherty R, Aljehane L, Kuo LW, Vakili S, Karna K, Clark H, McCarron E, Rosenthal DS. CD133 is associated with increased melanoma cell survival after multikinase inhibition. J. Oncol. 2019;2019:6486173. doi: https://doi.org/10.1155/2019/6486173
Sorokin M, Kholodenko R, Grekhova A, Suntsova M, Pustovalova M, Vorobyeva N, Kholodenko I, Malakhova G, Garazha A, Nedoluzhko A, Vasilov R, Poddubskaya E, Kovalchuk O, Adamyan L, Prassolov V, Allina D, Kuzmin D, Ignatev K, Osipov A, Buzdin A. Acquired resistance to tyrosine kinase inhibitors may be linked with the decreased sensitivity to X-ray irradiation. Oncotarget. 2017;9(4):5111-5124. doi: https://doi.org/10.18632/oncotarget.23700
Su YJ, Lin WH, Chang YW, Wei KC, Liang CL, Chen SC, Lee JL. Polarized cell migration induces cancer type-specific CD133/integrin/Src/Akt/GSK3β/β-catenin signaling required for maintenance of cancer stem cell properties. Oncotarget. 2015;6(35):38 029-38 045. doi: https://doi.org/10.18632/oncotarget.5703
Tsunekuni K, Konno M, Haraguchi N, Koseki J, Asai A, Matsuoka K, Kobunai T, Takechi T, Doki Y, Mori M, Ishii H. CD44/CD133-positive colorectal cancer stem cells are sensitive to trifluridine exposure. Sci Rep. 2019;9(1):14861. doi: https://doi.org/10.1038/s41598-019-50968-6
Wu Y, Wu PY. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev. 2009;18(8):1127-1134. doi: https://doi.org/10.1089/scd.2008.0338
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Kletochnye Tekhnologii v Biologii i Meditsine, No. 1, pp. 54-61, March, 2021
Rights and permissions
About this article
Cite this article
Kholodenko, I.V., Kim, Y.S., Gisina, A.M. et al. Analysis of the Correlation between CD133 Expression on Human Colorectal Adenocarcinoma Cells HT-29 and Their Resistance to Chemotherapeutic Drugs. Bull Exp Biol Med 171, 156–163 (2021). https://doi.org/10.1007/s10517-021-05188-2
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-021-05188-2